Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 19/20 | 0.89 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.89 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6113143 | 0.94 | MKNK2 (1.00) | MKNK2MKNK1 | |
| SCHEMBL6112962 | 0.92 | MKNK2 (0.88) | MKNK2MKNK1 | |
| SCHEMBL3802162 | 0.89 | MKNK2 (0.84) | MKNK2MKNK1 | |
| SCHEMBL12318086 | 0.88 | MKNK2 (0.81) | MKNK2MKNK1 | |
| SCHEMBL12318263 | 0.88 | MKNK2 (0.81) | MKNK2MKNK1 | |
| SCHEMBL17875350 | 0.84 | MKNK2 (0.78) | MKNK2MKNK1 | |
| SCHEMBL6113382 | 0.83 | MKNK2 (0.62) | MKNK2MKNK1 | |
| SCHEMBL2815778 | 0.82 | MKNK2 (0.71) | MKNK2MKNK1 | |
| SCHEMBL3805841 | 0.79 | MKNK2 (0.68) | MKNK2MKNK1 | |
| SCHEMBL13402708 | 0.79 | MKNK2 (0.68) | MKNK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331551-B1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INTERNAT GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| EP-2331551-B1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INTERNAT GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-8486953-B2 | Thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8486953-B2 | Thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8486953-B2 | Thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20120128686-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120128686-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120128686-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2010023181-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128686-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | MKNK2 18/4885MKNK1 56/4885SHMT2 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.